Test of CD47-SIRPα Inhibitors on the Immune Microenvironment Colon Cancer
About this study
Our goal is to create novel CD47-SIRPα inhibitors using small molecules to reverse TAM-mediated immune suppression and restore anti-tumor immunity in CRCs. Our program uses structure-based drug design to create selective and potent small molecule inhibitors of SIRPα-CD47 to target the tumor microenvironment with greater efficacy and lower toxicity than CD47-targeting antibodies. . In order to study the activity of CD47-SIRPα inhibitors on the immune microenvironment of tumors, we propose to use organoids derived from biopsies of patients with colon cancer. Tumoroids preserve the patient's tumor stroma (including myeloid cells) and provide an accurate in vitro model of complex tumor immune interaction for the evaluation of immunotherapies.
- Condition
- Cancer of the Colon
- Tested
- BLOOD AND TUMOR
- Sponsor
- Institut Paoli-Calmettes
Who can join
- Age
- 18 years and older
- Sex
- All sexes
- Healthy volunteers
- Not accepted
Inclusion 6
- Minimum age: 18 years
- Study condition: Cancer of the Colon
- Patient over 18 years old
- Patient who has signed a consent to participate;
- Patient with metastatic or non-metastatic colon cancer, or recurrence of colon cancer for whom excision surgery has been proposed;
- Patient affiliated to a social security scheme, or beneficiary of such a scheme
Exclusion 4
- Patient who had emergency colon cancer surgery
- Person in an emergency situation or unable to express their consent.
- Adult subject to a legal protection measure (adult under guardianship, curatorship or safeguard of justice),
- Patient unable to submit to the medical follow-up of the trial for geographical, social or psychological reasons
Where
1 site, 1 recruiting
Institut Paoli Calmettes
Marseille, France
Contact
-
Dominique GENRE, MD
+33491223778 drci.up@ipc.unicancer.fr
Potential match only. Final eligibility is determined by the study team.